The Mayo Clinic Experience with the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab

Michael W. Ruff, Michelle M Mauermann

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Neurological complications are an increasingly recognized complication of the use of the immune checkpoint inhibitors in the treatment of solid tumors. Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, an immune checkpoint inhibitor that suppresses T-cell effector function. The clinical spectrum of ipilimumab-associated neurological complications and optimum treatment approach is not established. We describe our institution's experience with ipilimumab and illustrate 2 cases of presumed autoimmune neurological phenomenon resulting from its use.

Original languageEnglish (US)
Pages (from-to)98-99
Number of pages2
JournalNeurologist
Volume23
Issue number3
DOIs
StatePublished - Jan 1 2018

Keywords

  • checkpoint inhibitors
  • CTLA-4
  • general neurology
  • ipilimumab
  • neurological complications

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'The Mayo Clinic Experience with the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab'. Together they form a unique fingerprint.

Cite this